Chronic Cluster Headache with Daily Attacks When Acute Nasal Spray Therapy Fails to Provide Relief

Clinical scenario

This protocol applies to the chronic form of cluster headache (ICHD-3 3.1.2), a less common presentation affecting fewer than 20% of cluster headache patients. Attacks occur on a daily basis; any symptom-free periods, if present at all, last fewer than 3 months — with this pattern sustained for at least 1 year.

Prior treatment — failure condition

This next-line protocol is indicated when acute attack therapy has not achieved the key goal of headache relief within 30 minutes of treatment. The acute therapies that may have been attempted include:

Zolmitriptan nasal spray
Sumatriptan nasal spray
Dihydroergotamine nasal spray
Lidocaine nasal instillation

Treatment goals

The target for this preventive protocol is at least a 50% reduction in attack frequency, with the preventive effect expected to be established within 2 to 3 weeks of initiation.

Approach — partial overview

The protocol is centred on an oral preventive agent that is carefully titrated upward, with obligatory cardiac monitoring throughout. Bridging strategies are available to manage attacks during the initial weeks while the preventive effect is being established.

Full regimen, sequencing, titration scheme, and monitoring details are in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ene.15956

In patients suffering from the less common chronic presentation (<20% of cluster headaches, ICHD-3 3.1.2), attacks often occur on a daily basis; if symptom-free periods are experienced, these last <3 months, for at least 1 year.
Initial preventive treatment of cluster headache is usually verapamil at a daily dose of at least 240 mg.
In clinical practice, most clinicians start up with 80 mg 3–4 times per day.
Based on consensus, ergotamine tartrate or frovatriptan are also recommended for short-term prevention.
Pharmacological nerve block of the GON is recommended and can be repeated if efficacious.
The responder rate defined as 50% reduction in headache frequency was 80%.

View source ↗